Scalp cooling versus standard cold-cap in preventing chemotherapy-induced alopecia in patients with localized breast cancer: ICELAND protocol, a randomized controlled trial and economic evaluation
PLOS One · 13.08.2026 · 21 (8) · e0354676
DOI: 10.1371/journal.pone.0354676 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, online erschienen am 13.08.2026. Verfasst von François Gernier und 16 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Department, Centre François Baclesse, Caen, France. Hauptthemen laut MEDLINE: Alopecia, Breast Neoplasms, Scalp, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PAXMAN, French Health Ministry.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Chemotherapy-induced alopecia (CIA) remains one of the most distressing adverse effects for patients with localized breast cancer receiving anthracycline and taxane-based chemotherapy regimens. Although automated scalp cooling systems and standard non-automated cold-cap devices have demonstrated efficacy in reducing CIA, controlled trials with direct randomization comparing these two modalities of scalp cooling are lacking. This study aims to compare clinical efficacy, patient-reported outcomes, and medico-economic impact of a scalp cooling system (PAXMAN® PSCS 2) versus standard cold-cap therapy in preventing CIA. Methods/Design ICELAND is a prospective, multicenter, open-label, randomized controlled phase III trial conducted in three French cancer centers. This study addresses female adult patients with histologically confirmed, non-metastatic breast cancer, scheduled to receive neoadjuvant or adjuvant chemotherapy with epirubicin-cyclophosphamide (3 or 4 cycles) followed by either docetaxel (3 cycles) or paclitaxel (9–12 weekly cycles) as per routine practice. A total of 196 patients will be 1:1 randomized to automated scalp cooling device (experimental arm) or standard non-automated cold-cap therapy (control arm), with stratification on chemotherapy regimen, menopausal status and centre. The primary endpoint is the proportion of patients experiencing no more than half hair loss (NCI-CTCAE v5.0 grade 0–1) from baseline to chemotherapy completion, as assessed by blinded central review of standardized photographs. Secondary endpoints include: degree of CIA before taxane initiation; hair regrowth 6 months after the end of chemotherapy; patient adherence and comfort for each scalp cooling modality; body image (BIS); quality of life (EORTC QLQ-C30/BR23); anxiety/depression (HADS); satisfaction with care (OUTPATSAT-35-CT); return to work; nursing time associated with device use; and cost-utility in QALYs.
Discussion
This study will provide the first high-quality randomized evidence directly comparing scalp cooling and standard cold-cap use for CIA prevention in localized breast cancer. The results will inform both clinical practice and health policy by integrating clinical efficacy, patient-reported outcomes, and medico-economic considerations.
Trial registration
ClinicalTrials.gov NCT06011525
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Research Department, Centre François Baclesse, Caen, France.
- ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), INSERM Unit 1086, Caen, France.
- Medical Oncology Department, Centre François Baclesse, Caen France.
- Breast pathway nurse, Centre François Baclesse, Caen, France.
- Assistance Publique-Hôpitaux de Paris, DRCI-URC Eco Ile-de-France, Paris, France.
- Université de Paris, Research Centre of Research Epidemiology and Statistics (CRESS-UMR1153), Inserm, Paris, France.
ORCID-Profile: Adeline Morel, Isabelle Durand-Zaleski, Bénédicte Clarisse
Förderung
- PAXMAN
- French Health Ministry
Zitieren
APA
Gernier, F., Lequesne, J., Grellard, J. M., Fernette, M., Gigan, L., Morel, A., Estienne, A., Castel, H., Lahaye, F., Leroux, T., Charles, R. M., Dupont, C., Zarca, K., Dereumaux, N., Rouanet, A. C., Durand-Zaleski, I., & Clarisse, B. (2026). Scalp cooling versus standard cold-cap in preventing chemotherapy-induced alopecia in patients with localized breast cancer: ICELAND protocol, a randomized controlled trial and economic evaluation. PLOS One, 21(8), e0354676. https://doi.org/10.1371/journal.pone.0354676
Vancouver
Gernier F, Lequesne J, Grellard JM, Fernette M, Gigan L, Morel A, et al. Scalp cooling versus standard cold-cap in preventing chemotherapy-induced alopecia in patients with localized breast cancer: ICELAND protocol, a randomized controlled trial and economic evaluation. PLOS One. 2026;21(8):e0354676. doi:10.1371/journal.pone.0354676
BibTeX
@article{Gernier2026,
author = {Gernier, François and Lequesne, Justine and Grellard, Jean-Michel and Fernette, Marie and Gigan, Laetitia and Morel, Adeline and Estienne, Adrien and Castel, Hervé and Lahaye, François and Leroux, Tiphaine and Charles, Rose-Marie and Dupont, Charlotte and Zarca, Kevin and Dereumaux, Nathalie and Rouanet, Anne-Cécile and Durand-Zaleski, Isabelle and Clarisse, Bénédicte},
title = {Scalp cooling versus standard cold-cap in preventing chemotherapy-induced alopecia in patients with localized breast cancer: ICELAND protocol, a randomized controlled trial and economic evaluation},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {8},
pages = {e0354676},
doi = {10.1371/journal.pone.0354676}
}
EUVIMED